Clark Capital Management Group’s Biogen BIIB Stock Holding History

Clark Capital Management Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,089	Closed	-$291K	–	347
2022 Q3	$291K	Sell	1,089 -4	-0.4%	-$850	﹤0.01%	315
2022 Q2	$223K	Buy	1,093 +115	+12%	+$23.5K	﹤0.01%	314
2022 Q1	$206K	Sell	978 -322	-25%	-$70K	﹤0.01%	357
2021 Q4	$312K	Buy	+1,300	New	+$334K	﹤0.01%	313
2019 Q2	–	Sell	-73,412	Closed	-$17.4M	–	293
2019 Q1	$17.4M	Sell	73,412 -4,516	-6%	-$1.42M	0.41%	103
2018 Q4	$23.4M	Buy	+77,928	New	+$24.9M	0.63%	64
2018 Q2	–	Sell	-63,734	Closed	-$17.5M	–	269
2018 Q1	$17.5M	Buy	63,734 +5,888	+10%	+$1.83M	0.55%	74
2017 Q4	$18.4M	Buy	+57,846	New	+$18.6M	0.56%	66
2017 Q3	–	Sell	-926	Closed	-$251K	–	295
2017 Q2	$251K	Sell	926 -15,804	-94%	-$4.18M	0.01%	245
2017 Q1	$4.57M	Sell	16,730 -17,949	-52%	-$5.08M	0.2%	118
2016 Q4	$9.83M	Buy	34,679 +5,749	+20%	+$1.7M	0.51%	65
2016 Q3	$9.06M	Buy	+28,930	New	+$8.57M	0.52%	57

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Clark Capital Management Group's BIIB Position: Q4 2022 in Review

Clark Capital Management Group sold out of Biogen (BIIB) in Q4 2022, closing a stake of 1,089 shares — an estimated $291K sold.

Clark Capital Management Group first reported a position in BIIB in Q3 2016 and held it in 12 quarters. The position peaked at $23.4M in Q4 2018. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Clark Capital Management Group reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Clark Capital Management Group sold 1,089 Biogen shares in Q4 2022, an estimated $291K.
Clark Capital Management Group first reported a position in Biogen in Q3 2016 and held it in 12 quarters.
Clark Capital Management Group's Biogen position peaked at $23.4M in Q4 2018.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Clark Capital Management Group's 13F filing for Q4 2022, filed 14 Feb 2023.